Literature DB >> 6889965

What do early bone scans tell about breast cancer patients?

N Rossing, O Munck, S P Nielsen, K W Andersen.   

Abstract

In 1978, 1012 out of a total of 1888 Danish breast cancer patients registered for a nationwide therapeutical trial were bone-scanned to find osseous metastases. A re-reading group (N.R., O.M. and S.P.N.) interpreted 842 of the scans produced in the twelve participating hospitals. Specific criteria were used for grading the scintiscans. Of the 842 scans 682 were performed within 30 days of the operation and were defined as initial. The re-reading group found 50 (7%) of these scans to be equivocal and 46 (7%) to be indicative of bone metastases at the time of operation. The number of X-ray-verified bone metastases was only 5 (0.6%). The frequency of positive bone scans correlated with the age of the patients and tumor size, but not with clinical staging at the time of operation, number of positive axillary lymph nodes or degree of tumor anaplasia. Recurrences and death rates during a 2-yr follow-Up period correlated significantly with initial clinical staging. In the clinical low-risk group a positive initial bone scan worsened the prognosis, but this was not statistically significant for all patients grouped together. Although the prognostic value of the initial bone scan per se is dubious, it serves as a guidance for elective X-ray examination and as a basis for comparing subsequent scans.

Entities:  

Mesh:

Year:  1982        PMID: 6889965     DOI: 10.1016/0277-5379(82)90208-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  9 in total

1.  Computer-aided quantitative bone scan assessment of prostate cancer treatment response.

Authors:  Matthew S Brown; Gregory H Chu; Hyun J Kim; Martin Allen-Auerbach; Cheryce Poon; Juliette Bridges; Adria Vidovic; Bharath Ramakrishna; Judy Ho; Michael J Morris; Steven M Larson; Howard I Scher; Jonathan G Goldin
Journal:  Nucl Med Commun       Date:  2012-04       Impact factor: 1.690

2.  Clinical surveillance for early stage breast cancer: an analysis of claims data.

Authors:  M S Simon; M Stano; R K Severson; M S Hoff; D W Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer.

Authors:  M S Simon; M Stano; M Hussein; M Hoff; D Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Objective evaluation of scintigraphic diagnosis of bone metastasis.

Authors:  A Allende-Riera; J Hdez-Armas; C Oton-Sanchez
Journal:  Eur J Nucl Med       Date:  1987

5.  The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.

Authors:  Nishikant Avinash Damle; Chandrasekhar Bal; G P Bandopadhyaya; Lalit Kumar; Praveen Kumar; Arun Malhotra; Sneh Lata
Journal:  Jpn J Radiol       Date:  2013-02-02       Impact factor: 2.374

6.  Breast cancer surveillance--a cost-effective strategy.

Authors:  D V Schapira
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology.

Authors:  M S Simon; M Hoff; M Hussein; S Martino; A Walt
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

8.  Quality of planar whole-body bone scan interpretations--a nationwide survey.

Authors:  May Sadik; Madis Suurkula; Peter Höglund; Andreas Järund; Lars Edenbrandt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-29       Impact factor: 9.236

9.  Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.

Authors:  Mehmet Halit Yilmaz; Mustafa Ozguroglu; Devrim Mert; Hande Turna; Gökhan Demir; Ibrahim Adaletli; Sila Ulus; Metin Halac; Kaya Kanberoğlu
Journal:  Med Oncol       Date:  2007-11-27       Impact factor: 3.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.